Department of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Kidney Int. 2021 Jul;100(1):19-21. doi: 10.1016/j.kint.2021.04.023.
Apolipoprotein L1 (APOL1) high-risk genotypes strongly associate with HIV-associated nephropathy, and antiretroviral therapy reduces the incidence of HIV-associated nephropathy and progression to end-stage kidney disease. Wudil et al. report cross-sectional APOL1 associations with proteinuria and estimated glomerular filtration rate in a northern Nigerian sample with HIV infection on antiretroviral therapy. Multiple ethnic groups with different APOL1 risk variant frequencies were included. Overall, APOL1 was associated with proteinuric chronic kidney disease; however, relationships with underlying causes of nephropathy and progression rates require further study.
载脂蛋白 L1 (APOL1) 高风险基因型与 HIV 相关肾病密切相关，而抗逆转录病毒治疗可降低 HIV 相关肾病的发病率和进展为终末期肾病的风险。Wudil 等人报告了在接受抗逆转录病毒治疗的尼日利亚北部 HIV 感染者的横断面研究中，APOL1 与蛋白尿和估计肾小球滤过率的关系。该研究纳入了多个具有不同 APOL1 风险变异频率的种族群体。总的来说，APOL1 与蛋白尿性慢性肾脏病相关；然而，与肾病的潜在病因和进展速度的关系还需要进一步研究。
